country,region,used_in_global_model,geo_level,sample,date started,date completed,result,N,unweighted positive,test,source
Afghanistan,Afghanistan,Yes,1,National sample,2020-07-15,2020-08-03,31.5,"9,500",,"Unknown (""survey which was done according to the WHO, Johns Hopkins University and USAID standards"")",http://www.afghanistantimes.af/afghanistan-has-10m-covid-19-infections-survey/
Australia,Australia,Yes,1,"individuals, providing blood samples at 10 hospital sites across 4 states in Australia in May and June 2020. These individuals were enrolled in a prospective cohort study to determine the prevalence of asymptomatic SARS-CoV-2 infection in individuals undergoing elective surgery in Australia",2020-06-02,2020-06-17,0.28,2991,,ELISA-based approach to that combines data about IgG responses to both the Nucleocapsid and Spike-receptor binding domain antigens,https://www.medrxiv.org/content/10.1101/2020.09.09.20191031v1
Belgium,Belgium,Yes,1,"serum bank covering all Belgian regions was constituted by collecting 120 residual sera from ten private diagnostic laboratories in Belgium. Large laboratories were engaged, 121 with high daily throughput covering primary care and all kinds of ambulatory specialist care outside 122 hospital. To avoid overrepresentation of subjects with acute and/or severe illness, samples collected in 123 hospitals were excluded",2020-06-29,2020-07-04,4.5,"3,023",,"Serology results were obtained 151 through a semi-quantitative test kit (EuroImmun, Luebeck, Germany), measuring IgG antibodies 152 against S1 proteins of SARS-CoV-2 in serum (ELISA).",https://www.medrxiv.org/content/10.1101/2020.06.08.20125179v2
Belgium,Belgium,Yes,1,"serum bank covering all Belgian regions was constituted by collecting 120 residual sera from ten private diagnostic laboratories in Belgium. Large laboratories were engaged, 121 with high daily throughput covering primary care and all kinds of ambulatory specialist care outside 122 hospital. To avoid overrepresentation of subjects with acute and/or severe illness, samples collected in 123 hospitals were excluded",2020-06-08,2020-06-13,5.5,"2,960",,"Serology results were obtained 151 through a semi-quantitative test kit (EuroImmun, Luebeck, Germany), measuring IgG antibodies 152 against S1 proteins of SARS-CoV-2 in serum (ELISA).",https://www.medrxiv.org/content/10.1101/2020.06.08.20125179v2
Belgium,Belgium,Yes,1,"serum bank covering all Belgian regions was constituted by collecting 120 residual sera from ten private diagnostic laboratories in Belgium. Large laboratories were engaged, 121 with high daily throughput covering primary care and all kinds of ambulatory specialist care outside 122 hospital. To avoid overrepresentation of subjects with acute and/or severe illness, samples collected in 123 hospitals were excluded",2020-04-18,2020-05-25,6.9,"3,242",,"Serology results were obtained 151 through a semi-quantitative test kit (EuroImmun, Luebeck, Germany), measuring IgG antibodies 152 against S1 proteins of SARS-CoV-2 in serum (ELISA).",https://www.medrxiv.org/content/10.1101/2020.06.08.20125179v2
Belgium,Belgium,Yes,1,"serum bank covering all Belgian regions was constituted by collecting 120 residual sera from ten private diagnostic laboratories in Belgium. Large laboratories were engaged, 121 with high daily throughput covering primary care and all kinds of ambulatory specialist care outside 122 hospital. To avoid overrepresentation of subjects with acute and/or severe illness, samples collected in 123 hospitals were excluded",2020-04-20,2020-04-26,6,"3,397",,"Serology results were obtained 151 through a semi-quantitative test kit (EuroImmun, Luebeck, Germany), measuring IgG antibodies 152 against S1 proteins of SARS-CoV-2 in serum (ELISA).",https://www.medrxiv.org/content/10.1101/2020.06.08.20125179v2
Belgium,Belgium,Yes,1,"serum bank covering all Belgian regions was constituted by collecting 120 residual sera from ten private diagnostic laboratories in Belgium. Large laboratories were engaged, 121 with high daily throughput covering primary care and all kinds of ambulatory specialist care outside 122 hospital. To avoid overrepresentation of subjects with acute and/or severe illness, samples collected in 123 hospitals were excluded",2020-03-30,2020-04-05,2.9,"3,910",,"Serology results were obtained 151 through a semi-quantitative test kit (EuroImmun, Luebeck, Germany), measuring IgG antibodies 152 against S1 proteins of SARS-CoV-2 in serum (ELISA).",https://www.medrxiv.org/content/10.1101/2020.06.08.20125179v2
Brazil,Brazil,Yes,1,random sample from 133 sentinel cities in 26 Brazilian 111 states and the Federal District (Figure 1),2020-05-14,2020-05-21,1.4,"25,025",,"WONDFO 459 SARS-CoV-2 Antibody Test (Wondfo Biotech Co., Guangzhou, China), using finger 460 prick blood samples",https://www.medrxiv.org/content/10.1101/2020.05.30.20117531v1.full.pdf
Brazil,Brazilian State of Rio Grande do Sul,FALSE,,random sample,2020-04-25,2020-04-27,0.1333,"4,500",,The Wondfo lateral flow rapid test for detecting antibodies against SARS-CoV-2,https://www.medrxiv.org/content/10.1101/2020.05.01.20087205v2.full.pdf
Brazil,Brazilian State of Rio Grande do Sul,FALSE,,random sample,2020-04-11,2020-04-13,0.0477,"4,188",,The Wondfo lateral flow rapid test for detecting antibodies against SARS-CoV-2,https://www.medrxiv.org/content/10.1101/2020.05.01.20087205v2.full.pdf
China,Guangzhou,FALSE,,"These visitors, including inpatients and their healthy companions, represented a population with a common social exposure and without COVID-19-related symptoms.",NA,2020-04-30,0.6,"8,782",,,https://www.nature.com/articles/s41422-020-0371-0
China,Wuhan,FALSE,,"hospital visitors inc. inpatients and their healthy companions, a population with a common social exposure and without COVID-19-related symptoms.",NA,2020-04-30,2.1,"8,272",,,https://www.nature.com/articles/s41422-020-0371-0
China,Wuhan,FALSE,,most of the analyzed medical records were based on examinees directed by their work units. Most of the examinees came from government-owned institutions and agencies instead of private businesses,2020-03-25,2020-04-28,2.72,"18,712",3.51,SARS-CoV-2 antibody detection kits (colloidal gold method) were provided by INNOVITA,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3.full.pdf
China,Wuhan,FALSE,,most of the analyzed medical records were based on examinees directed by their work units. Most of the examinees came from government-owned institutions and agencies instead of private businesses,2020-04-24,2020-04-28,2.23,"1,998",1.45,SARS-CoV-2 antibody detection kits (colloidal gold method) were provided by INNOVITA,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3.full.pdf
China,Wuhan,FALSE,,most of the analyzed medical records were based on examinees directed by their work units. Most of the examinees came from government-owned institutions and agencies instead of private businesses,2020-04-19,2020-04-23,1.56,"2,534",2.21,SARS-CoV-2 antibody detection kits (colloidal gold method) were provided by INNOVITA,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3.full.pdf
China,Wuhan,FALSE,,most of the analyzed medical records were based on examinees directed by their work units. Most of the examinees came from government-owned institutions and agencies instead of private businesses,2020-04-14,2020-04-18,2.18,"6,695",2.79,SARS-CoV-2 antibody detection kits (colloidal gold method) were provided by INNOVITA,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3.full.pdf
China,Wuhan,FALSE,,most of the analyzed medical records were based on examinees directed by their work units. Most of the examinees came from government-owned institutions and agencies instead of private businesses,2020-04-09,2020-04-13,3.18,"4,046",3.58,SARS-CoV-2 antibody detection kits (colloidal gold method) were provided by INNOVITA,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3.full.pdf
China,Chengdu,FALSE,,"""Community resident""",2020-03-09,2020-04-10,0.6,"9,442",,,https://www.nature.com/articles/s41591-020-0949-6/tables/1
China,Chongqing,FALSE,,Outpatients,2020-03-09,2020-04-10,3.8,993,,,https://www.nature.com/articles/s41591-020-0949-6/tables/1
China,Wuhan,FALSE,,most of the analyzed medical records were based on examinees directed by their work units. Most of the examinees came from government-owned institutions and agencies instead of private businesses,2020-04-04,2020-04-08,7.67,"1,222",8.43,SARS-CoV-2 antibody detection kits (colloidal gold method) were provided by INNOVITA,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3.full.pdf
China,Wuhan,FALSE,,most of the analyzed medical records were based on examinees directed by their work units. Most of the examinees came from government-owned institutions and agencies instead of private businesses,2020-03-30,2020-04-03,4.18,"1,694",5.14,SARS-CoV-2 antibody detection kits (colloidal gold method) were provided by INNOVITA,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3.full.pdf
China,Wuhan,FALSE,,most of the analyzed medical records were based on examinees directed by their work units. Most of the examinees came from government-owned institutions and agencies instead of private businesses,2020-03-25,2020-03-29,2.98,523,3.82,SARS-CoV-2 antibody detection kits (colloidal gold method) were provided by INNOVITA,https://www.medrxiv.org/content/10.1101/2020.06.16.20132423v3.full.pdf
Denmark ,Denmark,Yes,1,Danish blood donors aged 17–69 years,2020-04-06,2020-05-03,1.9,"20,640",,,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa849/5862661
Ethiopia,Addis Ababa,Yes,3,"Age 14 years or 72 higher; resident in Addis Ababa for all of November 2019-February 2020 and no travel outside 73 Ethiopia since November 1, 2019.The following exclusion criteria also were absent: sore 74 throat, runny nose, cough or difficulty breathing and/or hospitalized or quarantined in the last 28 75 days; measured temperature>99.6 Fahrenheit, resting heart rate >100/minut, and/or resting 76 respiratory rate ≥25/minute); incarceration for a crime; unwilling to participate; or unable to 77 consent.",2020-05-18,2020-05-21,3.03,99,,Abbott IgG test run on the ARCHITECT platform,https://www.medrxiv.org/content/10.1101/2020.06.23.20137521v1
Germany,Germany,Yes,1,Adult blood donors,2020-04-01,2020-08-19,1.25,"30,000",1.87,"IgG ELISA, corrected for false negatives / positives",https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Projekte_RKI/SeBluCo_Zwischenbericht.html
Germany,Bonn,Yes,3,"all individuals who were enrolled in the Rhineland Study, an ongoing community-based prospective cohort study in people aged 30 years and above",2020-04-24,2020-06-30,0.97,"4,771",,"Anti-SARS-CoV-2 IgG levels were measured using an ELISA assay, and all positive or borderline results were subsequently examined through both a recombinant immunofluorescent assay and a plaque reduction neutralisation test (PRNT).",https://www.medrxiv.org/content/10.1101/2020.08.24.20181206v1
Germany,Hesse,Yes,2,Residual material leftover from routine diagnostics ,2020-03-09,2020-06-03,0.66,910,,"ELISA, showed a high specificity of 99–100% and a sensitivity of ca65% [6-9].",https://www.eurosurveillance.org/docserver/fulltext/eurosurveillance/25/28/eurosurv-25-28-2.pdf?expires=1600446928&id=id&accname=guest&checksum=806D133AC79AFC3EFBD4EC8BDF973DA0
Germany,Lower Saxony,Yes,2,Residual material leftover from routine diagnostics ,2020-03-09,2020-06-03,1.22,576,,"ELISA, showed a high specificity of 99–100% and a sensitivity of ca65% [6-9].",https://www.eurosurveillance.org/docserver/fulltext/eurosurveillance/25/28/eurosurv-25-28-2.pdf?expires=1600446928&id=id&accname=guest&checksum=806D133AC79AFC3EFBD4EC8BDF973DA0
Germany,North Rhine-Westphalia,Yes,2,Residual material leftover from routine diagnostics ,2020-03-09,2020-06-03,0.91,"1,700",,"ELISA, showed a high specificity of 99–100% and a sensitivity of ca65% [6-9].",https://www.eurosurveillance.org/docserver/fulltext/eurosurveillance/25/28/eurosurv-25-28-2.pdf?expires=1600446928&id=id&accname=guest&checksum=806D133AC79AFC3EFBD4EC8BDF973DA0
Greece,Greece,Yes,1,"blood samples collected, individuals who visited the laboratories for a check-up, chronic disease follow-up or other reasons unrelated to COVID-19",2020-04-01,2020-04-30,0.49,"4,511",,"ABBOTT SARS-CoV-2 IgG assay, a chemiluminescent microparticle immunoassay (CMIA), with the ARCHITECT i2000SR analyzer (Abbott, Illinois, United States)",https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369#html_fulltext
Greece,Greece,Yes,1,"blood samples collected, individuals who visited the laboratories for a check-up, chronic disease follow-up or other reasons unrelated to COVID-19",2020-03-01,2020-03-31,0.27,"2,075",,"ABBOTT SARS-CoV-2 IgG assay, a chemiluminescent microparticle immunoassay (CMIA), with the ARCHITECT i2000SR analyzer (Abbott, Illinois, United States)",https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.31.2001369#html_fulltext
Iceland,Iceland,Yes,1,random-population screening,2020-03-13,2020-04-04,0.8,"13,080",,LUH or deCODE Genetics with the use of similar quantitative real-time polymerase-chain-reaction (qRT-PCR) assay methods,https://www.nejm.org/doi/10.1056/NEJMoa2006100
India,Andhra Pradesh,FALSE,,,2020-08-07,2020-09-11,19.7,"74,000",,IgG antibodies using the Chemiluminescence Enzyme Immunoassays or CLIA method.,https://theprint.in/health/andhras-second-sero-survey-begins-today-45000-samples-to-be-collected-from-9-districts/489208/
India,Chennai,FALSE,,,NA,2020-09-01,21.5,"12,405","2,673",,https://www.indiatoday.in/india/story/chennai-sero-survey-findings-covid-coronavirus-transmission-1717489-2020-09-01
India,Ahmedanbad,FALSE,,,2020-08-15,2020-08-29,23.24,"10,310",,,https://indianexpress.com/article/cities/ahmedabad/second-survey-in-ahmedabad-sero-positivity-up-by-5-6-per-cent-since-june-no-herd-immunity-yet-6580951/
India,Indore,FALSE,,Aged 1 and above,NA,2020-08-29,7.72,"7,103",548,,https://www.indiatoday.in/india/story/indore-sero-survey-antibodies-found-nearly-people-1716506-2020-08-29
India,Delhi,FALSE,,,2020-08-01,2020-08-07,29.1,"15,000",4500,,https://www.indiatoday.in/india/story/delhi-covid-19-2nd-delhi-sero-survey-results-1713145-2020-08-20
India,Mumbai,FALSE,,"the three wards of R North (Dahisar), M West (Chembur) and F North, percentage extrapolated from slum and non-slum residents to combined slum and non-slum population",2020-07-06,2020-07-20,33,"6,936",,,https://timesofindia.indiatimes.com/city/mumbai/57-of-mumbai-slumdwellers-have-covid-antibodies-sero-survey/articleshow/77231640.cms
India,Ahmedanbad,FALSE,,,2020-06-16,2020-07-11,17.61,"30,054",,,https://indianexpress.com/article/cities/ahmedabad/second-survey-in-ahmedabad-sero-positivity-up-by-5-6-per-cent-since-june-no-herd-immunity-yet-6580951/
India,Delhi,FALSE,,,2020-06-27,2020-07-10,23,"21,387",4900,,https://www.indiatoday.in/india/story/coronavirus-delhi-sero-survey-report-herd-immunity-low-mortality-rate-experts-1703034-2020-07-22
India,India,Yes,1,"a randomly sampled, community-based survey was conducted in 700 villages/wards, selected from the 70 districts of the 21 States of India, categorized into four strata based on the incidence of reported COVID-19 cases. Four hundred adults per district were enrolled from 10 clusters with one adult per household.",2020-05-11,2020-06-04,0.73,"28,000",,Covid-19 Kavach ELISA detection kit.,http://www.ijmr.org.in/preprintarticle.asp?id=294807;type=0
India ,Pune,FALSE,,"high-incidence areas only, ranging from 36.1 per cent to 65.4 per cent in selected areas sampled in Pune city",NA,NA,51.5,"1,664",,,https://indianexpress.com/article/cities/pune/first-sero-survey-shows-extensive-spread-of-covid-19-from-36-1-to-65-4-in-selected-areas-sampled-in-pune-6558853/
Iran,Guilan province,Yes,2,population-based cluster random sampling design,2020-04-01,2020-04-23,22,551,,,https://www.medrxiv.org/content/10.1101/2020.04.26.20079244v1.full.pdf
Ireland,Ireland,Yes,1,12-69 year-olds randomly selected from the communities in Sligo and Dublin,2020-06-22,2020-07-16,1.7,"1,733",1.9,Abbott Architect SARS-CoV-2 IgG Assay to detect antibodies (IgG),https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/scopi/SCOPI%20report%20preliminary%20results%20final%20version.pdf
Italy,Abruzzo,Yes,2,random sampling of population,2020-05-25,2020-07-15,1.5,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Basilicata,Yes,2,random sampling of population,2020-05-25,2020-07-15,0.8,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Bolzano/Bozen,Yes,2,random sampling of population,2020-05-25,2020-07-15,3.3,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Calabria,Yes,2,random sampling of population,2020-05-25,2020-07-15,0.6,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Campania,Yes,2,random sampling of population,2020-05-25,2020-07-15,0.7,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Emilia-Romagna,Yes,2,random sampling of population,2020-05-25,2020-07-15,2.8,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Friuli-Venezia Giulia,Yes,2,random sampling of population,2020-05-25,2020-07-15,1,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Italy,Yes,1,random sampling of population,2020-05-25,2020-07-15,2.5,"64,660",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Lazio,Yes,2,random sampling of population,2020-05-25,2020-07-15,1,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Liguria,Yes,2,random sampling of population,2020-05-25,2020-07-15,3.1,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Lombardia,Yes,2,random sampling of population,2020-05-25,2020-07-15,7.5,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Marche,Yes,2,random sampling of population,2020-05-25,2020-07-15,2.7,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Molise,Yes,2,random sampling of population,2020-05-25,2020-07-15,0.7,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Piemonte,Yes,2,random sampling of population,2020-05-25,2020-07-15,3,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Puglia,Yes,2,random sampling of population,2020-05-25,2020-07-15,0.9,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Sardegna,Yes,2,random sampling of population,2020-05-25,2020-07-15,0.3,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Sicilia,Yes,2,random sampling of population,2020-05-25,2020-07-15,0.3,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Toscana,Yes,2,random sampling of population,2020-05-25,2020-07-15,1,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Trento,Yes,2,random sampling of population,2020-05-25,2020-07-15,3.1,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Umbria,Yes,2,random sampling of population,2020-05-25,2020-07-15,0.9,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Valle d'Aosta/Vallée…,Yes,2,random sampling of population,2020-05-25,2020-07-15,4,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Italy,Veneto,Yes,2,random sampling of population,2020-05-25,2020-07-15,1.9,"3,000",,,http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5012
Japan,Kobe,FALSE,,patients at outpatient settings,2020-03-31,2020-04-07,2.7,"1,000",3.3,"immunochromatographic test to detect IgG against SARS-CoV-2 was used for the analysis (RCNC002, KURABO Industries Lt)",https://www.medrxiv.org/content/10.1101/2020.04.26.20079822v1.full.pdf
Kenya,Kenya,Yes,1,blood transfusion donors15-17 or expectant mothers attending ante-natal clinics,2020-04-30,2020-06-16,5.2,"3,098",5.6,Krammer Enzyme linked Immunosorbent assay (ELISA),https://www.medrxiv.org/content/10.1101/2020.07.27.20162693v1.full.pdf
Malaysia,Kuala Lumpur and Selangor State,FALSE,,residual serum samples collected at a teaching hospital serving Kuala Lumpur and Selangor state,2020-04-15,2020-06-06,0.4,261,0.5,"first screened with an in‐house indirect enzyme‐linked immunosorbent assay (ELISA) detecting IgG to SARS‐CoV‐2 receptor binding domain (RBD), and shown to be 100% sensitive for samples collected from 14 days postonset of illness.3 Screen‐seropositive samples were confirmed with a highly sensitive and specific (99.3%‐100%) surrogate viral neutralization test (sVNT; cPass, GenScript) based on total antibody‐mediated blockage of angiotensin‐converting enzyme 2 receptor‐RBD interaction,",https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26426
Malaysia,Kuala Lumpur and Selangor State,FALSE,,residual serum samples collected at a teaching hospital serving Kuala Lumpur and Selangor state,2020-01-29,2020-04-14,0.4,327,0.6,"first screened with an in‐house indirect enzyme‐linked immunosorbent assay (ELISA) detecting IgG to SARS‐CoV‐2 receptor binding domain (RBD), and shown to be 100% sensitive for samples collected from 14 days postonset of illness.3 Screen‐seropositive samples were confirmed with a highly sensitive and specific (99.3%‐100%) surrogate viral neutralization test (sVNT; cPass, GenScript) based on total antibody‐mediated blockage of angiotensin‐converting enzyme 2 receptor‐RBD interaction,",https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26426
Netherlands,Netherlands,Yes,1,blood donors,2020-05-09,2020-05-18,5.5,"7,000",,,https://www.tweedekamer.nl/downloads/document?id=e7f03364-2f26-4703-9636-706b4826f59e&title=Presentatie%20de%20heer%20Van%20Dissel%20-%20RIVM.pdf
Netherlands,Netherlands,Yes,1,"random sample of population. In early June, the initial study participants and a number of additional participants were asked to do their own finger-stick blood test up to 6 times over the next 1.5 years.",2020-04-01,2020-04-17,3.6,"2,096",,,https://www.rivm.nl/en/novel-coronavirus-covid-19/children-and-covid-19
Netherlands,Netherlands,Yes,1,blood donors,2020-04-01,2020-04-15,3.5,"4,000",,,https://www.sanquin.nl/over-sanquin/nieuws/2020/08/sanquin-onderzoek-mensen-kunnen-slecht-inschatten-of-ze-corona-hebben
Nigeria,Niger State,FALSE,,"clustered-stratified-Random sampling, numbers cited exclude health care workers (who otherwise would have been 25 percent and had much higher rates",2020-06-26,2020-06-30,19.01,142,,COVID-19 IgG and IgM Rapid Test Kits (Colloidal gold immunochromatography lateral flow system),https://www.medrxiv.org/content/10.1101/2020.08.04.20168112v1
Norway,Norway,Yes,1,"blood samples collected from labs, excluding those submitted to be tested for sars-covid-2 originally",2020-04-20,2020-05-11,0.9,900,,"novel in-house assay established at the Department of Immunology, Oslo University Hospital",https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2020/covid-19/seroprevalence-of-sars-cov-2-in-the-norwegian-population_report-26-06-2020.pdf
Pakistan,Urban areas,FALSE,,"large scale census conducted on a dense, urban, working population in Pakistan",,2020-07-06,17.5,"24,210",,gG/IgM Test Kit (Colloidal gold),https://www.medrxiv.org/content/10.1101/2020.08.13.20173914v1
Russia,Moscow,FALSE,,Random sample of city population,2020-06-05,2020-06-18,19.9,"90,000",,,https://www.themoscowtimes.com/2020/06/26/1-in-5-moscow-residents-have-coronavirus-antibodies-official-a70712
Russia,Russia,Yes,1,"Testing in all 46 regions of the country, country-wide effort",2020-06-01,2020-06-10,14,"650,000",,,https://www.interfax.ru/russia/712617
Russia,St. Petersburg,FALSE,,Random sample of city population,2020-05-18,2020-06-07,5.7,490,8,,https://eusp.org/en/news/press-release-6-of-people-in-st-petersburg-russia-have-had-covid-19-0
Russia,Moscow,FALSE,,random sampling of population,2020-05-15,2020-05-28,14,"70,000",,ELISA  IgM antibodies in the patient's blood (a marker of the presence of coronavirus infection) and IgG (a marker of immunity to coronavirus infection,https://www.interfax.ru/moscow/710758
Spain,Albacete,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,10.8,"1,051",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Alicante/Alacant,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,3,"1,564",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Almería,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,3.4,901,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Araba/Álava,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,6.4,772,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Ávila,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,8,661,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Badajoz,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,2.7,"1,577",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,"Balears, Illes",Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,1.4,"1,280",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Barcelona,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,7.3,"3,664",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Bizkaia,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,3.6,"1,277",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Burgos,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,5.7,900,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Cáceres,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,3.9,"1,163",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Cádiz,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,2.6,"1,324",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Cantabria,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,3.7,"1,670",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Castellón/Castelló,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,2.7,838,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Ceuta,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,0.7,906,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Ciudad Real,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,9.1,"1,147",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Córdoba,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,2.7,"1,087",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,"Coruña, A",Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,1.6,"1,208",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Cuenca,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,11.4,803,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Gipuzkoa,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,2.5,"1,065",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Girona,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,2.7,"1,065",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Granada,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,3.5,"1,050",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Guadalajara,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,9.8,844,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Huelva,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,1.2,962,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Huesca,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,5,678,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Jaén,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,4.4,"1,022",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,León,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,6.4,934,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Lleida,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,2.9,815,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Lugo,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,1.5,766,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Madrid,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,11.7,"3,732",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Málaga,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,3.6,"1,343",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Melilla,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,3.4,907,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Ourense,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,2.5,748,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Palencia,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,6.6,783,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,"Palmas, Las",Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,2.2,"1,400",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Pontevedra,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,2.1,"1,150",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,"Principado, Asturias",Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,1.9,"1,703",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,"Rioja, La",Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,3.7,"1,356",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Salamanca,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,9.5,836,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Santa Cruz Tenerife,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,2.4,"1,193",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Segovia,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,12.4,705,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Sevilla,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,2.7,"1,697",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Soria,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,14.4,713,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Spain,Yes,1,random sample recruited through national serosurvey,2020-06-08,2020-06-22,5.2,"62,167",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Tarragona,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,1.5,946,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Teruel,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,4.9,647,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Toledo,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,8.6,"1,099",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Valencia/València,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,2,"1,987",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Valladolid,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,7.4,"1,060",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Zamora,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,7.3,678,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Zaragoza,Yes,2,random sample recruited through national serosurvey,2020-06-08,2020-06-22,4.7,"1,289",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Albacete,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,11.5,"1,098",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Alicante/Alacant,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,3.3,"1,671",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Almería,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,2.5,946,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Araba/Álava,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,6.2,727,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Ávila,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,8.3,677,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Badajoz,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,2.9,"1,599",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,"Balears, Illes",Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,1.5,"1,344",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Barcelona,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,7.4,"3,793",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Bizkaia,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,3.8,"1,247",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Burgos,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,5.3,922,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Cáceres,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,3.9,"1,191",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Cádiz,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,2.4,"1,382",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Cantabria,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,3.2,"1,661",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Castellón/Castelló,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,3.8,865,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Ceuta,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,0.5,904,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Ciudad Real,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,9.7,"1,175",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Córdoba,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,2.5,"1,112",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,"Coruña, A",Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,2.2,"1,243",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Cuenca,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,14.8,835,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Gipuzkoa,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,2.6,"1,020",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Girona,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,3.1,991,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Granada,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,3.3,"1,090",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Guadalajara,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,10.6,867,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Huelva,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,1.2,"1,006",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Huesca,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,4.7,707,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Jaén,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,4.4,"1,050",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,León,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,5.7,935,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Lleida,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,3.4,831,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Lugo,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,2.5,790,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Madrid,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,11.4,"3,704",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Málaga,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,3.5,"1,453",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Melilla,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,3.2,926,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Ourense,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,2.2,750,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Palencia,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,8.2,767,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,"Palmas, Las",Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,2.1,"1,478",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Pontevedra,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,2,"1,216",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,"Principado, Asturias",Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,1.6,"1,712",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,"Rioja, La",Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,3.8,"1,402",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Salamanca,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,8.3,858,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Santa Cruz Tenerife,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,3.2,"1,227",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Segovia,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,12.6,721,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Sevilla,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,2.7,"1,784",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Soria,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,14.6,720,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Spain,Yes,1,random sample recruited through national serosurvey,2020-05-18,2020-06-01,5.2,"63,666",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Tarragona,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,1.6,992,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Teruel,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,3.5,671,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Toledo,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,8.8,"1,198",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Valencia/València,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,2.1,"2,007",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Valladolid,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,7.2,"1,082",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Zamora,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,6.2,662,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Zaragoza,Yes,2,random sample recruited through national serosurvey,2020-05-18,2020-06-01,5.2,"1,299",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Albacete,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,11.7,"1,058",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Alicante/Alacant,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,2.6,"1,573",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Almería,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,1.6,986,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Araba/Álava,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,7.4,692,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Ávila,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,6.6,667,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Badajoz,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,2.6,"1,583",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,"Balears, Illes",Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,2.3,"1,372",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Barcelona,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,7,"3,696",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Bizkaia,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,4,"1,195",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Burgos,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,4.9,887,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Cáceres,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,3,"1,201",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Cádiz,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,1.6,"1,385",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Cantabria,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,3.6,"1,504",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Castellón/Castelló,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,2.9,803,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Ceuta,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,1.2,838,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Ciudad Real,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,10.2,"1,163",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Córdoba,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,2.6,"1,117",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,"Coruña, A",Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,1.8,"1,275",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Cuenca,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,13.2,851,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Gipuzkoa,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,2.5,951,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Girona,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,2.6,905,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Granada,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,2.8,"1,024",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Guadalajara,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,10.4,814,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Huelva,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,1.2,930,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Huesca,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,4.4,733,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Jaén,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,4,"1,062",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,León,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,6.1,886,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Lleida,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,3.8,710,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Lugo,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,2.2,813,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Madrid,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,11.3,"3,186",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Málaga,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,4,"1,463",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Melilla,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,1.8,927,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Ourense,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,2.9,686,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Palencia,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,8,740,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,"Palmas, Las",Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,1.9,"1,244",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Pontevedra,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,2.2,"1,296",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,"Principado, Asturias",Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,1.9,"1,550",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,"Rioja, La",Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,3.4,"1,324",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Salamanca,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,7.5,809,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Santa Cruz Tenerife,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,2.7,"1,124",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Segovia,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,11.8,548,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Sevilla,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,2.3,"1,805",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Soria,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,14.4,707,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Spain,Yes,1,random sample recruited through national serosurvey,2020-04-27,2020-05-11,5,"35,883",,chemiluminescent microparticle immunoassay,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31483-5/fulltext
Spain,Tarragona,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,1.4,"1,012",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Teruel,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,3.3,688,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Toledo,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,8.9,"1,179",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Valencia/València,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,2.1,"1,913",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Valladolid,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,5.9,"1,084",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Zamora,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,6.8,651,,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Spain,Zaragoza,Yes,2,random sample recruited through national serosurvey,2020-04-27,2020-05-11,4.9,"1,331",,anticuerpos IgG anti SARS-CoV-2 por provincia (test rápido),https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf
Sweden,"Rinkeby-Kista, Stockholm",Yes,3,"Random sample, 16 to 70 years old",2020-06-22,2020-06-24,18.7,538,,"Unilabs med Abbott Architect 1 SARS-CoV-2IgG assay samt konfirmering av svagt reaktiva med DiaSorin Liaison SARS-CoV-2 S1/S2 IgG assay (3,4). ",https://www.folkhalsomyndigheten.se/globalassets/statistik-uppfoljning/smittsamma-sjukdomar/veckorapporter-covid-19/2020/covid-19-veckorapport-vecka-36-final_v2.pdf
Sweden,Sweden,Yes,1,Blood donors,2020-06-08,2020-06-14,6.3,400,,multiplex metod (Sci Life Lab/KTH),https://www.folkhalsomyndigheten.se/contentassets/376f9021a4c84da08de18ac597284f0c/pavisning-antikroppar-genomgangen-covid-19-blodgivare-delrapport-2.pdf
Sweden,Sweden,Yes,1,"outpatient clinics, weighted to reflect population",2020-06-08,2020-06-14,5.6,"1,200",,multiplex metod (Sci LifeLab/KTH),https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf
Sweden,Sweden,Yes,1,"outpatient clinics, weighted to reflect population",2020-06-01,2020-06-07,7,"1,200",,multiplex metod (Sci LifeLab/KTH),https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf
Sweden,Sweden,Yes,1,Blood donors,2020-06-01,2020-06-07,5.2,400,,multiplex metod (Sci Life Lab/KTH),https://www.folkhalsomyndigheten.se/contentassets/376f9021a4c84da08de18ac597284f0c/pavisning-antikroppar-genomgangen-covid-19-blodgivare-delrapport-2.pdf
Sweden,Sweden,Yes,1,"outpatient clinics, weighted to reflect population",2020-05-25,2020-05-31,5.6,"1,200",,multiplex metod (Sci LifeLab/KTH),https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf
Sweden,Sweden,Yes,1,Blood donors,2020-05-25,2020-05-31,4,400,,multiplex metod (Sci Life Lab/KTH),https://www.folkhalsomyndigheten.se/contentassets/376f9021a4c84da08de18ac597284f0c/pavisning-antikroppar-genomgangen-covid-19-blodgivare-delrapport-2.pdf
Sweden,Sweden,Yes,1,"outpatient clinics, weighted to reflect population",2020-05-18,2020-05-24,5.4,"1,200",,multiplex metod (Sci LifeLab/KTH),https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf
Sweden,Sweden,Yes,1,Blood donors,2020-05-18,2020-05-24,5.1,400,,multiplex metod (Sci Life Lab/KTH),https://www.folkhalsomyndigheten.se/contentassets/376f9021a4c84da08de18ac597284f0c/pavisning-antikroppar-genomgangen-covid-19-blodgivare-delrapport-2.pdf
Sweden,Sweden,Yes,1,Blood donors,2020-05-11,2020-05-17,5.2,400,,multiplex metod (Sci Life Lab/KTH),https://www.folkhalsomyndigheten.se/contentassets/376f9021a4c84da08de18ac597284f0c/pavisning-antikroppar-genomgangen-covid-19-blodgivare-delrapport-2.pdf
Sweden,Sweden,Yes,1,"outpatient clinics, weighted to reflect population",2020-05-11,2020-05-17,4.6,"1,200",,multiplex metod (Sci LifeLab/KTH),https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf
Sweden,Sweden,Yes,1,"outpatient clinics, weighted to reflect population",2020-05-04,2020-05-10,4.1,"1,200",,multiplex metod (Sci LifeLab/KTH),https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf
Sweden,Sweden,Yes,1,Blood donors,2020-05-04,2020-05-10,2.9,400,,multiplex metod (Sci Life Lab/KTH),https://www.folkhalsomyndigheten.se/contentassets/376f9021a4c84da08de18ac597284f0c/pavisning-antikroppar-genomgangen-covid-19-blodgivare-delrapport-2.pdf
Sweden,Sweden,Yes,1,"outpatient clinics, weighted to reflect population",2020-04-27,2020-05-03,4.1,"1,200",,multiplex metod (Sci LifeLab/KTH),https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf
Sweden,Sweden,Yes,1,Blood donors,2020-04-27,2020-05-03,2.6,400,,multiplex metod (Sci Life Lab/KTH),https://www.folkhalsomyndigheten.se/contentassets/376f9021a4c84da08de18ac597284f0c/pavisning-antikroppar-genomgangen-covid-19-blodgivare-delrapport-2.pdf
Sweden,Sweden,Yes,1,"outpatient clinics, weighted to reflect population",2020-04-20,2020-04-26,5.2,"1,200",,multiplex metod (Sci LifeLab/KTH),https://www.folkhalsomyndigheten.se/contentassets/9c5893f84bd049e691562b9eeb0ca280/pavisning-antikroppar-genomgangen-covid-19-blodprov-oppenvarden-delrapport-1.pdf
Sweden,Sweden,Yes,1,Blood donors,2020-04-20,2020-04-26,0.7,400,,multiplex metod (Sci Life Lab/KTH),https://www.folkhalsomyndigheten.se/contentassets/376f9021a4c84da08de18ac597284f0c/pavisning-antikroppar-genomgangen-covid-19-blodgivare-delrapport-2.pdf
Sweden,Sweden,Yes,1,Blood donors,2020-03-23,2020-03-29,0,400,,multiplex metod (Sci Life Lab/KTH),https://www.folkhalsomyndigheten.se/contentassets/376f9021a4c84da08de18ac597284f0c/pavisning-antikroppar-genomgangen-covid-19-blodgivare-delrapport-2.pdf
Sweden,Sweden,Yes,1,Blood donors,2020-03-16,2020-03-22,0,400,,multiplex metod (Sci Life Lab/KTH),https://www.folkhalsomyndigheten.se/contentassets/376f9021a4c84da08de18ac597284f0c/pavisning-antikroppar-genomgangen-covid-19-blodgivare-delrapport-2.pdf
Switzerland,Canton of Geneva,Yes,2,"random sample, similar demographics to canton at large",2020-05-04,2020-05-10,10.8,775,,anti-SARS-CoV-2-IgG antibodies using a commercially available ELISA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext
Switzerland,Canton of Geneva,Yes,2,"random sample, similar demographics to canton at large",2020-04-27,2020-05-03,6.6,604,,anti-SARS-CoV-2-IgG antibodies using a commercially available ELISA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext
Switzerland,Canton of Geneva,Yes,2,"random sample, similar demographics to canton at large",2020-04-20,2020-04-26,10.9,577,,anti-SARS-CoV-2-IgG antibodies using a commercially available ELISA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext
Switzerland,Canton of Geneva,Yes,2,"random sample, similar demographics to canton at large",2020-04-13,2020-04-19,8.5,469,,anti-SARS-CoV-2-IgG antibodies using a commercially available ELISA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext
Switzerland,Canton of Geneva,Yes,2,"random sample, similar demographics to canton at large",2020-04-06,2020-04-12,4.8,341,,anti-SARS-CoV-2-IgG antibodies using a commercially available ELISA,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext
United Kingdom,East Midlands,Yes,2,national sample of above 16 population,2020-04-26,2020-08-27,3.9,701,,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,East of England,Yes,2,national sample of above 16 population,2020-04-26,2020-08-27,6.4,918,,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,England,Yes,2,national sample of above 16 population,2020-04-26,2020-08-27,6.02,"7,093",,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,London,Yes,2,national sample of above 16 population,2020-04-26,2020-08-27,11,540,,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,North East,Yes,2,national sample of above 16 population,2020-04-26,2020-08-27,4.9,226,,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,North West,Yes,2,national sample of above 16 population,2020-04-26,2020-08-27,4.8,886,,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,South East,Yes,2,national sample of above 16 population,2020-04-26,2020-08-27,4.7,"1,232",,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,South West,Yes,2,national sample of above 16 population,2020-04-26,2020-08-27,3.5,"1,165",,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,West Midlands,Yes,2,national sample of above 16 population,2020-04-26,2020-08-27,6.8,684,,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,Yorkshire and the Humber,Yes,2,national sample of above 16 population,2020-04-26,2020-08-27,5.2,741,,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,East Midlands,Yes,2,national sample of above 16 population,2020-04-26,2020-08-23,3.9,701,25,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,East of England,Yes,2,national sample of above 16 population,2020-04-26,2020-08-23,6.4,918,57,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,England,Yes,2,national sample of above 16 population,2020-04-26,2020-08-23,6.02,"7,093",350,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,London,Yes,2,national sample of above 16 population,2020-04-26,2020-08-23,11,540,52,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,North East,Yes,2,national sample of above 16 population,2020-04-26,2020-08-23,4.9,226,13,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,North West,Yes,2,national sample of above 16 population,2020-04-26,2020-08-23,4.8,886,49,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,South East,Yes,2,national sample of above 16 population,2020-04-26,2020-08-23,4.7,"1,232",52,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,South West,Yes,2,national sample of above 16 population,2020-04-26,2020-08-23,3.5,"1,165",31,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,West Midlands,Yes,2,national sample of above 16 population,2020-04-26,2020-08-23,6.8,684,42,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,Yorkshire and the Humber,Yes,2,national sample of above 16 population,2020-04-26,2020-08-23,5.2,741,29,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,England,Yes,2,national sample of above 16 population,2020-04-26,2020-08-09,6.24,"5,248",,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,England,Yes,2,national sample of above 16 population,2020-04-26,2020-07-26,6.21,"4,840",,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,England,Yes,2,national sample of above 16 population,2020-04-26,2020-07-08,6.29,"4,309",,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,England,Yes,2,national sample of above 16 population,2020-04-26,2020-06-27,6.3,"3,298",,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,England,Yes,2,national sample of above 16 population,2020-04-26,2020-06-08,5.4,"1,757",,,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata
United Kingdom,East of England,Yes,2,"healthy blood donors, weighted to be representative",2020-05-04,2020-05-10,10,"1,000",,Euroimmun assay,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata/2030
United Kingdom,North West,Yes,2,"healthy blood donors, weighted to be representative",2020-05-04,2020-05-10,12.4,"1,000",,Euroimmun assay,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata/2027
United Kingdom,London,Yes,2,"healthy blood donors, weighted to be representative",2020-04-27,2020-05-03,17.5,"1,000",,Euroimmun assay,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata/2022
United Kingdom,South East,Yes,2,"healthy blood donors, weighted to be representative",2020-04-20,2020-05-03,4.8,"1,000",,Euroimmun assay,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata/2029
United Kingdom,Midlands,Yes,2,"healthy blood donors, weighted to be representative",2020-04-20,2020-04-26,8,"1,000",,Euroimmun assay,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata/2024
United Kingdom,North West,Yes,2,"healthy blood donors, weighted to be representative",2020-04-13,2020-04-26,6.4,"1,000",,Euroimmun assay,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata/2026
United Kingdom,South West,Yes,2,"healthy blood donors, weighted to be representative",2020-04-20,2020-04-26,4.9,"1,000",,Euroimmun assay,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata/2028
United Kingdom,London,Yes,2,"healthy blood donors, weighted to be representative",2020-04-06,2020-04-19,12.3,"1,000",,Euroimmun assay,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata/2021
United Kingdom,North East,Yes,2,"healthy blood donors, weighted to be representative",2020-04-13,2020-04-19,4.2,"1,000",,Euroimmun assay,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata/2025
United Kingdom,Midlands,Yes,2,"healthy blood donors, weighted to be representative",2020-03-30,2020-04-05,1.5,"1,000",,Euroimmun assay,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata/2023
United Kingdom,London,Yes,2,"healthy blood donors, weighted to be representative",2020-03-23,2020-03-29,1.5,"1,000",,Euroimmun assay,https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata/2020
United States,Minnesota,Yes,3,blood samples collected by commercial laboratories as part of routine patient care.,2020-06-15,2020-06-27,4.34,"1,667",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Utah,Yes,2,blood samples collected by commercial laboratories as part of routine patient care.,2020-06-15,2020-06-24,1.52,"1,976",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,New York City Metro Area,Yes,3,blood samples collected by commercial laboratories as part of routine patient care.,2020-06-15,2020-06-21,19.47,"1,581",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Missouri,Yes,2,blood samples collected by commercial laboratories as part of routine patient care.,2020-06-15,2020-06-20,0.84,"1,850",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Philadelphia Metro Area,Yes,3,blood samples collected by commercial laboratories as part of routine patient care.,2020-06-14,2020-06-20,3.78,"1,694",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Western Washington Region,Yes,3,blood samples collected by commercial laboratories as part of routine patient care.,2020-06-15,2020-06-20,1.69,"1,803",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Connecticut,Yes,2,blood samples collected by commercial laboratories as part of routine patient care.,2020-06-15,2020-06-17,6.27,"1,798",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Minnesota,Yes,3,blood samples collected by commercial laboratories as part of routine patient care.,2020-05-25,2020-06-07,2.18,"1,323",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Utah,Yes,2,blood samples collected by commercial laboratories as part of routine patient care.,2020-05-25,2020-06-05,1.14,"1,940",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Missouri,Yes,2,blood samples collected by commercial laboratories as part of routine patient care.,2020-05-25,2020-05-30,2.8,"1,831",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Philadelphia Metro Area,Yes,3,blood samples collected by commercial laboratories as part of routine patient care.,2020-05-26,2020-05-30,3.63,"1,743",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Connecticut,Yes,2,blood samples collected by commercial laboratories as part of routine patient care.,2020-05-21,2020-05-26,5.18,"1,800",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Minnesota,Yes,3,blood samples collected by commercial laboratories as part of routine patient care.,2020-04-30,2020-05-12,2.35,860,,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Western Washington Region,Yes,3,blood samples collected by commercial laboratories as part of routine patient care.,2020-04-27,2020-05-11,2.06,"1,719",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,New York City Metro Area,Yes,3,blood samples collected by commercial laboratories as part of routine patient care.,2020-04-25,2020-05-06,23.2,"1,116",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Connecticut,Yes,2,blood samples collected by commercial laboratories as part of routine patient care.,2020-04-26,2020-05-03,4.94,"1,431",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Utah,Yes,2,blood samples collected by commercial laboratories as part of routine patient care.,2020-04-20,2020-05-03,2.18,"1,132",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,San Francisco Bay Area,Yes,3,blood samples collected by commercial laboratories as part of routine patient care.,2020-04-23,2020-04-27,0.97,"1,224",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Missouri,Yes,2,blood samples collected by commercial laboratories as part of routine patient care.,2020-04-20,2020-04-26,2.65,"1,882",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Philadelphia Metro Area,Yes,3,blood samples collected by commercial laboratories as part of routine patient care.,2020-04-13,2020-04-25,3.19,824,,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,South Florida,Yes,3,blood samples collected by commercial laboratories as part of routine patient care.,2020-04-20,2020-04-24,2.85,"1,280",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Los Angeles,Yes,3,A random sample of residents,2020-04-10,2020-04-14,4.65,863,4.34,SARS-CoV-2–specific antibodies using a lateral flow immunoassay test (Premier Biotech),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235907/
United States,South Florida,Yes,3,blood samples collected by commercial laboratories as part of routine patient care.,2020-04-06,2020-04-10,1.85,"1,742",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Louisiana,Yes,2,blood samples collected by commercial laboratories as part of routine patient care.,2020-04-01,2020-04-08,5.75,"1,184",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,New York City Metro Area,Yes,3,blood samples collected by commercial laboratories as part of routine patient care.,2020-03-23,2020-04-01,6.93,"2,482",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html
United States,Western Washington Region,Yes,3,blood samples collected by commercial laboratories as part of routine patient care.,2020-03-23,2020-04-01,1.13,"3,264",,,https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/commercial-lab-surveys.html